Mark Aldersley

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal et al. · The Lancet · 2015 · 2K citations · Full text

Placebo-controlled Phase 2, Liraglutide Safety, Hepatology +5

The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitis

Marco Carbone, Stephen J. Sharp, Steve Flack et al. · Hepatology · 2015 · 335 citations

Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

Marco Carbone, Alessandra Nardi, Steve Flack et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 158 citations · Full text

Hepatology, Pretreatment Prediction, Biliary Tract +7

Patterns of acid reflux in complicated oesophagitis.

Duncan A. Robertson, Mark Aldersley, H A Shepherd et al. · Gut · 1987 · 126 citations · Full text

Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use

Jessica Dyson, John M. Hutchinson, Olorunda Rotimi et al. · Journal of Hepatology · 2015 · 94 citations · Full text

Hepatitis C Virus, Pathology, Pharmacotherapy +22